Safety profile of bevacizumab on cultured human corneal cells.

Safety profile of bevacizumab on cultured human corneal cells. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Safety profile of bevacizumab on cultured human corneal cells. Abstract Text:

Efdal Yoeruek,Martin S Spitzer,Olcay Tatar,Sabine Aisenbrey,Karl U Bartz-Schmidt,Peter Szurman,Efdal Yoeruek,Martin S Spitzer,Olcay Tatar,Sabine Aisenbrey,Karl U Bartz-Schmidt,Peter Szurman,

PURPOSE: To study the corneal biocompatibility of bevacizumab on various cultured human corneal cells. METHODS: Cell cultures of corneal keratinocytes (CKs), corneal fibroblasts (CFs), and corneal endothelial cells (CECs) were harvested from human donor eyes and exposed to various concentrations of bevacizumab (0.25-5.0 mg/mL). Cell viability was assessed by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay at days 1 and 4 after exposure. For cytotoxicity testing, confluent cells were cultured in serum-depleted medium, and the MTT test was performed after 24 hours of incubation. Expression of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR1 and VEGFR2), keratan sulphate (KS), and cytokeratin-3 (AE5) was studied by immunohistochemistry. Live/dead viability/cytotoxicity assay was performed and analyzed by fluorescence microscopy after 24 hours of incubation. Cell morphology was assessed with a phase-contrast microscope after 7 days of exposure with different concentrations of bevacizumab (0.25-5.0 mg/mL), and signs of cellular damage were assessed. RESULTS: No cytotoxic effect of bevacizumab on CKs, CFs, and CECs could be observed when used at a concentration of 5.0 mg/mL or lower. Bevacizumab-treated cells showed no signs of cellular damage compared with the control. CKs, CFs, and CECs stained positively for VEGF, VEGFR1, and VEGFR2. CKs and CECs stained positively for AE5, whereas CFs were immunopositive for KS. CONCLUSIONS: Bevacizumab is not toxic to corneal cells of human origin in vitro at doses usually used for treatment of corneal neovascularization, which is 20-fold higher than that used for intravitreal application.

Safety profile of bevacizumab on cultured human corneal cells. Publishing Authors By Initials

E Yoeruek,MS Spitzer,O Tatar,S Aisenbrey,KU Bartz-Schmidt,P Szurman,E Yoeruek,MS Spitzer,O Tatar,S Aisenbrey,KU Bartz-Schmidt,P Szurman,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Safety profile of bevacizumab on cultured human corneal cells. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cornea

VOLUME: 26

Page Numbers: 977-82

Journal Abbreviation: Cornea

ISSN: 0277-3740

DAY: 27

MONTH: Sep

YEAR: 2007

Safety profile of bevacizumab on cultured human corneal cells. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8216186

Safety profile of bevacizumab on cultured human corneal cells. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Safety profile of bevacizumab on cultured human corneal cells. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Safety profile of bevacizumab on cultured human corneal cells.

AFFILIATION: Department of Ophthalmology I, University of Tuebingen, Tuebingen, Germany.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cornea

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Safety profile of bevacizumab on cultured human corneal cells Related Publications

• August consultation #4.
• Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
• Effects of bevacizumab on retinal function in isolated vertebrate retina.
• Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema.
• Electrophysiological effects of Brilliant Blue G in the model of the isolated perfused vertebrate retina.
• Safety profile of a taurine containing irrigation solution (AcriProTect) in pars plana vitrectomy.
• Safety profile of bevacizumab on cultured human corneal cells.
• Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
• Suppression of melanoma-associated neoangiogenesis by bevacizumab.
• The effects of triamcinolone crystals on retinal function in a model of isolated perfused vertebrate retina.
• Toxic effects of recombinant tissue plasminogen activator on cultured human corneal endothelial cells.
• [Optic atrophy subsequent to epiretinal triamcinolone deposits in an eye following inner limiting membrane peeling.]